Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Acute Myeloid Leukemia peptide trials
2 selected ClinicalTrials.gov records carrying the official condition label Acute Myeloid Leukemia. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
2 selected records.
2 profiles.
2026–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 34 selected PubMed records and 7 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Acute Myeloid Leukemia unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT06810583
PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- September 15, 2026
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT07392970
PeptideScanner retained ClinicalTrials.gov record NCT07392970 at 2026-11-16T01:39:10.285Z. Its registry update date was 2026-07-24, and PeptideScanner's reviewed identity mapping was motixafortide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- July 24, 2026
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Dalbavancin · 2026-09-15
ClinicalTrials.gov record NCT06810583
Recruiting at the retained observation.
Open attributed record →Motixafortide · 2026-07-24
ClinicalTrials.gov record NCT07392970
Recruiting at the retained observation.
Open attributed record →